SCHEMBL650992

SCHEMBL650992

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccc(OC(F)F)cc1)Cc1ccc2c(ccn2C)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.41
CACNA1H O95180 1/20 0.40
HSD11B1 P28845 1/20 0.37
TSHR P16473 2/20 0.33
ALDH1A1 P00352 1/20 0.33
HTT P42858 1/20 0.33
LMNA P02545 1/20 0.33
BCHE P06276 2/20 0.32
SLC6A2 P23975 1/20 0.32
SLC6A4 P31645 1/20 0.32
SLC6A3 Q01959 1/20 0.32
CRHR1 P34998 1/20 0.31
FAAH O00519 1/20 0.31
DAGLA Q9Y4D2 1/20 0.30
DRD2 P14416 1/20 0.30
DRD3 P35462 1/20 0.30
ATP4A P20648 1/20 0.30
ATP4B P51164 1/20 0.30
CHRNA7 P36544 1/20 0.30
BACE1 P56817 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL649846 0.90 C5AR1 (0.47) C5AR1HSD11B1TSHRALDH1A1BCHE
SCHEMBL651033 0.90 C5AR1 (0.44) C5AR1HSD11B1TSHRALDH1A1HTT
SCHEMBL651956 0.89 C5AR1 (0.43) C5AR1HSD11B1TSHRALDH1A1HTT
SCHEMBL648790 0.88 C5AR1 (0.43) C5AR1TSHRALDH1A1HTTLMNA
SCHEMBL5135971 0.87 C5AR1 (0.41) C5AR1TSHRALDH1A1HTTLMNA
SCHEMBL650580 0.87 C5AR1 (0.41) C5AR1HSD11B1TSHRALDH1A1HTT
SCHEMBL652505 0.86 C5AR1 (0.42) C5AR1HSD11B1TSHRALDH1A1HTT
SCHEMBL648409 0.86 C5AR1 (0.42) C5AR1TSHRALDH1A1HTTLMNA
SCHEMBL649675 0.86 C5AR1 (0.42) C5AR1TSHRALDH1A1HTTLMNA
SCHEMBL651505 0.86 C5AR1 (0.40) C5AR1TSHRALDH1A1HTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed